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Abstract. Voltage-gated Na+ channels (VGSCs) are membrane 
proteins which are normally expressed in excitable cells 
but have also been detected in cancer cells, where they are 
thought to be involved in malignancy progression. In this 
study we examined the ion current and expression profile of 
VGSC (Nav1.5) in estrogen receptor (ER)-positive (MCF-7) 
and silenced (pII) breast cancer cells and its possible influence 
on their proliferation, motility and invasion. VGSC currents 
were analysed by whole cell patch clamp recording. Nav1.5 
expression and localization, in response to EGF stimulation, 
was examined by western blotting and immunofluorescence 
respectively. Cell invasion (under-agarose and Matrigel 
assays), motility (wound healing assay) and proliferation 
(MTT assay) were assessed in pII cells in response to VGSC 
blockers, phenytoin (PHT) and tetrodotoxin (TTX), or by 
siRNA knockdown of Nav1.5. The effect of PHT and TTX on 
modulating EGF-induced phosphorylation of Akt and ERK1/2 
was determined by western blotting. Total matrix metallopro-
teinase (MMP) was determined using a fluorometric-based 
activity assay. The level of various human proteases was 
detected by using proteome profiler array kit. VGSC currents 
were detected in pII cells, but were absent in MCF-7. Nav1.5 
showed cytoplasmic and perinuclear expression in both MCF-7 
and pII cells, with enhanced expression upon EGF stimulation. 
Treatment of pII cells with PHT, TTX or siRNA significantly 
reduced invasion towards serum components and EGF, in 
part through reduction of P-ERK1/2 and proteases such as 
cathepsin E, kallikrein-10 and MMP-7, as well as total MMP 
activity. At high concentrations, PHT inhibited motility while 
TTX reduced cell proliferation. Pharmacological or genetic 
blockade of Nav1.5 may serve as a potential anti-metastatic 
therapy for breast cancer.
Introduction
Breast cancer is the most frequently diagnosed neoplasm in 
women. In the majority of cases, hormonal manipulation by 
chemical or surgical oophorectomy, or by pharmacological 
intervention with anti-estrogens such as tamoxifen, remains 
one of the most effective approaches in the treatment of 
estrogen receptor (ER)-positive breast malignancies (1,2). Both 
de novo and acquired resistance to endocrine based therapies 
results from actual or functional loss of ER and is paralleled 
by cellular transition from an epithelial to a mesenchymal 
phenotype. Commonly referred to as EMT, this is associated 
with enhanced proliferative and invasive capacity and results 
in poor clinical outcome.
Voltage-gated sodium channels (VGSCs) are heteromeric 
membrane protein complexes containing a single pore-forming 
α subunit and one or more smaller auxiliary β subunits (3-7). 
They are classically responsible for initiation and propogation 
of action potential in excitable cells (8). They effect rapid Na+ 
influx coincident with efflux of intracellular K+. In mammals, 
ten genes encoding VGSCα have been described, nine of 
which constitute one family with designations of Nav1.1 to 
Nav1.9, and Nax (4,6,9-14). These isoforms are encoded by 
the genes SCN1A to SCN11A. VGSCα forms an ion pore that 
differs in its tetrodotoxin (TTX) sensitivity; being sensitive 
to either nanomolar (Nav1.1 to Nav1.4, Nav1.6 and Nav1.7) or 
micromolar (Nav1.5, Nav1.8 and Nav1.1) concentrations of the 
toxin (4,9,12,15). VGSCβ are also members of the immuno-
globulin superfamily of cell adhesion molecules (CAMs), and 
responsible for regulating channel gating (16). Four subunits 
of VGSCβ (β1-β4 encoded by the genes SCN1B to SCN4B) 
have been identified in mammals; β1, β1A/B, and β3 are non-
covalently bound to the α subunit, while β2 and β4 are linked 
by disulfide bonds. VGSCβ are multifunctional molecules; 
they boost channel kinetics, transfer voltage-dependence and 
expand channel expression in the cell membrane (17). These 
subunits also promote cell adhesion in vitro, both in the pres-
ence and absence of the α subunit (7). Thus they are expressed 
in non-excitable cells such as glia, human endothelial cells and 
T-lymphocytes (10,11). In addition, they have been found to be 
overexpressed in various forms of tumors, promoting adhesion, 
galvanotaxis, motility and invasion, and are therefore associ-
ated with poor clinical prognosis (9,11,18-21). For example, in 
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prostate cancer cells, enhanced expression of VGSCα subunit 
was observed in the highly metastatic cell line MAT-lylu/
PC-3 compared with the poorly metastatic cell line AT-2/
lNCaP (18), and tetrodotoxin treatment resulted in significant 
inhibition of PC3 cell invasion in vitro (20).
In breast cancer, the α subunit gene (SCN5A) and nNav1.5 
protein were found to be upregulated in the highly metastatic 
de novo resistant MdA-MB-231 cells, in contrast to the weakly 
metastatic MCF-7 (3,22), and are involved in the enhance-
ment of extracellular matrix (ECM) degradation (23), in part 
through activation of acidic cysteine cathepsins B and S (24).
We have established several endocrine-resistant breast 
cancer cell lines by shRNA-mediated silencing of ER. These 
have all undergone EMT, and acquired enhanced proliferative 
and invasive capacity towards various serum components, 
insulin-like growth factor-1 and epidermal growth factor (EGF) 
(25-27). Since VGSC expression/activity was shown to be 
enhanced in highly metastatic cancer cells, we were interested to 
test if this channel shows enhanced expression level and activity 
in our acquired form of endocrine-resistant breast cancer cells 
(pII), and if their invasive behavior is correlated with blockade 
of VGSC activity. In the present study, we examined the involv-
ment of VGSCs in these cells, with respect to functions related 
to tumor progression, either by inhibiting channel activity with 
pharmacological agents (phenytoin and tetrodotoxin) or through 
siRNA-mediated reduction of Nav1.5 channels. We show for the 
first time a pro-invasive effect of VGSCs in breast cancer cells 
with acquired endocrine resistance, modulated in part through 
enhancement of proteases (cathepsin E and kallikrein 10) and 
MMP (such as MMP-7) activity.
Materials and methods
Cell lines. MCF-7 breast cancer cells were obtained from the 
American Type Culture Collection (VA, USA). pII cell line 
(ER silenced) was established in our laboratory by transfec-
tion of MCF-7 with ER directed shRNA plasmid as described 
previously (25,27). For routine culture, all cell lines were 
maintained as monolayers in advanced dulbecco's minimum 
essential medium (dMEM) containing phenol red and 
supplemented with 5% fetal bovine serum (FBS), 600 µg/ml 
l-glutamine, 100 u/ml penicillin, 100 µg/ml streptomycin and 
6 ml/500 100X non-essential amino acids (all from Invitrogen, 
CA, uSA), and grown at 37˚C in an incubator gassed with an 
atmosphere of 5% CO2 and maintained at 95% humidity.
Drugs, reagents and antibodies. 5,5-diphenylhydantoin 
sodium salt (PHT; Sigma, uSA) was prepared by dissolution 
in NaOH and stored at -20˚C. Tetrodotoxin (TTX; Tocris, uK) 
was prepared by dissolution in physiological saline solution 
at pH 7.4, and stored at -80˚C. Stock solutions (10 mM) were 
diluted with PBS to give final concentrations of 100 nM, 1, 
10, 50 and 100 µM. EGF powder (Sigma) was re-suspended in 
0.1% BSA at 0.1 mg/ml, and stored in aliquots at -20˚C. This 
stock solution was freshly diluted with sterile PBS to give final 
concentrations of 10, 50 and 100 ng/ml. Phallotoxin and goat 
anti-rabbit IgG were obtained from Alexa. Anti-Nav1.5 anti-
body (ab56240) was obtained from Abcam, uK. P-ERK1/2, 
P-Akt, actin, and anti-HRP-conjugated secondary antibodies 
were obtained from Cell Signaling, uSA.
Electrophysiology. Membrane currents were recorded from 
cells grown on glass coverslips using the whole-cell patch clamp 
technique, as described previously (3,28). A Multiclamp 700B 
amplifier was used to make recordings in voltage clamp 
mode, compensating for series resistance by 40-60%. A 
Digidata 1440A interface (Molecular Devices) was used to digi-
tize currents, which were low-pass filtered at 10 kHz, sampled 
at 50 kHz and then analyzed using pClamp 10.4 software. 
linear leak currents were subtracted using a P/6 protocol (29).
MTT assay. Approximately 104 cells were seeded into tripli-
cate wells of 12-well plates and allowed to attach overnight. 
Either vehicle only (control) or VGSC inhibitors PHT or 
TTX (100 nM-100 µM) were then added to the cells. Growth 
was assessed after 4 days of incubation. Briefly, 1 ml of 
MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide] reagent (Promega, uSA) (0.5 mg/ml) was added to 
each well and plates incubated at 37˚C for 30 min followed 
by the addition of 1 ml acidic isopropanol and vigorous 
re-suspension of the converted blue dye. Absorbance of the 
suspension was measured at 595 nm with background subtrac-
tion at 650 nm.
Cell motility wound healing assay. pII cells were cultured in 
12-well plates to 80-90% confluency. A scratch was created in 
the cell monolayer using a sterile p100 yellow pipette tip and 
an image of the scratched area was captured immediately (0 h). 
The media was then replaced with vehicle (control), phenytoin, 
or TTX at concentrations of 100 nM, 1, 10, 50 and 100 µM 
diluted in DMEM. Cells were cultured at 37˚C/5% CO2. After 
24 h, an image was captured of the same scratched area. The 
width of the scratch at 24 h was calculated as a percentage of 
the width at 0 h; a minimum of 3 areas along the scratch were 
measured.
Agarose invasion assay. Ultra-pure agarose (Invitrogen) 
was melted in PBS, supplemented with dMEM containing 
5% FBS, and allowed to solidify in individual wells of 6-well 
dishes at room temperature. Once set, cells (4x104) that had 
been exposed to various concentrations of PHT or TTX, or 
vehicle (control), were loaded into wells in the agarose formed 
as previously described (26). Plates were incubated at 37˚C 
in 5% CO2 humidified atmosphere. After 24 h, cells that had 
penetrated into the agarose were manually counted by visual 
microscopic examination. Random cell invasion was deter-
mined as the total number of cells which moved in both lateral 
directions out of the well. In another experimental setup, cells 
were treated with EGF (10 ng/ml) in the presence or absence 
of various concentrations of PHT or TTX and invasion deter-
mined. In this latter case, the agarose was mixed with insulin 
transferrin selenium (ITS) instead of 5% FBS since serum 
itself has invasive stimulatory components.
Cultrex BME cell invasion assay. pII cell invasion was also 
assessed by the Cultrex® 24-well BME cell invasion assay 
obtained from Trevigen (uSA) according to the manufac-
turer's instructions. In brief, the invasion chamber was coated 
with 100 µl of 1X basement membrane extract (BME) solution 
and incubated overnight at 37˚C. pII cells serum-starved over-
night at 37˚C/5% CO2, were re-suspended at 106 cells/ml in 
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DMEM (control) or DMEM containing various doses of PHT 
(1, 10, 50 and 100 µM), and 100 µl of suspension was loaded 
into the upper chamber. The lower chamber was loaded with 
500 µl DMEM supplemented with 10% FBS, as a chemoat-
tractant. Cells were incubated at 37˚C, 5% CO2 and allowed 
to migrate from the top chamber to the bottom. After 48 h, 
liquid from both top and bottom chambers was removed by 
aspiration and chambers gently washed with 1X cell wash 
buffer, provided by the supplier. Calcein-AM/cell dissociation 
solution complex was added to the bottom chamber and left 
for 1 h at 37˚C/5% CO2. Cells internalize Calcein-AM and 
intracellular esterases cleave acetomethylester (AM) moiety 
generating fluorescent free calcein. Invading cells were 
determined by recording the fluorescence emission using 
a microplate reader with a filter set of excitation/emission = 
485/535 nm (Cultrex, 2008).
Confocal microscopy. MCF-7 and pII cells grown overnight 
at 37˚C, 5% CO2 in 8-well glass chambered slides (Lab-Tek, 
uSA) were either left untreated or exposed for 30 min to 
EGF (50 ng/ml) then fixed with 3.7% paraformaldehyde 
and stained with phallotoxin (green fluorescence) to visu-
alize F-actin, Nav1.5 antibody (red fluorescence), and DAPI 
(blue fluorescence) to visualize the nuclei, and examined by 
confocal microscopy using a Carl Zeiss lSM 700 micro-
scope.
Western blotting. pII cells were cultured in 6-well plates to 
80% confluence and then serum-starved overnight before 
addition of either vehicle or EGF (50 ng/ml). After 30-min 
exposure cells were harvested by scraping into 300 µl of lysis 
buffer containing 50 mM HEPES, 50 mM NaCl, 5 mM EDTA 
1% Triton X-100, 100 µg/ml PMSF, 10 µg/ml aprotinin, and 
10 µg/ml leupeptin. Protein was determined by the standard 
Bradford assay and 6 µg were mixed with an equal volume of 
2X SDS and heated at 90˚C for 10 min. lysates were loaded 
onto a 10% SdS-polyacrylamide gel and electrophoresed at 
150 V for 1 h. Proteins were transferred to a nitrocellulose 
membrane and blocked with 2% BSA for 1 h before being 
incubated overnight at 4˚C with either total or pAkt antibody 
(1/600 dilution), pERK1/2 antibody (1/1,000 dilution), Nav1.5 
antibody (1/100 dilution), or actin antibody (1/1,000 dilution) 
prepared in 2% BSA. The membrane was washed and incu-
bated with anti-HRP-conjugated secondary antibody (1/500 
dilution) for 1 h, developed with Super Signal ECl and visual-
ized with Kodak X-ray film.
Matrix metalloproteinase activity. The general activity 
of MMPs was determined using a kit from Abcam (cat 
no. ab112146) according to the manufacturer's protocol. 
pII cells were seeded into 6-well plates and allowed to grow to 
80% confluence. Cells were serum starved overnight, and then 
either left untreated or exposed to 100 µM phenytoin for 1 h 
followed by EGF stimulation (100 ng/ml) for 30 min. Then, 
25 µl of the media was removed and added to 25 µl of 2 mM 
APMA working solution and incubated for 15 min at 25˚C, 
followed by addition of 50 µl of green substrate solution. MMP 
activity was measured at 10-min intervals for 1 h, at 37˚C by 
recording fluorescence emission using a microplate reader 
with a filter set of excitation/emission = 485/535 nm.
Proteome profiler analysis. The relative change in 35 human 
proteases was detected using Proteome Profiler™ human 
protease array kit (cat no. ARY021B, R&d Systems, Inc., 
Minneapolis, MN, uSA) following the manufacturer's 
protocol. Briefly, pII cells were cultured in 6-well plates until 
reaching 80-90% confluency, then serum-starved overnight, 
and either left untreated (uT, control) or exposed to 50 µM 
phenytoin for 1 h followed by EGF stimulation (100 ng/ml) for 
30 min. Cell lysate was harvested by scraping into 300 µl of 
lysis buffer containing 50 mM HEPES, 50 mM NaCl, 5 mM 
EDTA 1% Triton X-100, 100 µg/ml PMSF, 10 µg/ml aprotinin, 
and 10 µg/ml leupeptin. Protein was determined by the stan-
dard Bradford assay. Nitrocellulose membranes with duplicate 
spots of selected capture antibodies were incubated in 2 ml 
of array buffer 6 (works as blocking buffer) in 4-well multi-
dishes on a rocking platform for 1 h. For each membrane, 
protein samples (200 µg) were incubated at room temperature 
with 15 µl of protease detection cocktail for 1 h, before adding 
onto the membrane, and incubated overnight at 4˚C. The 
membranes were then washed with 1X wash buffer and incu-
bated with streptavidin HRP for 30 min. Following another 
wash, the membranes were incubated with chemi-reagent 
mix and exposed for 10-20 min. Spot intensity was quantified 
using a densitometer and the average of duplicate spots on the 
membrane was normalized with the average negative control 
spots according to the manufacturer's protocol.
siRNA transfection. pII cells were plated in 12-well plates 
in complete DMEM and incubated for 18 h at 37˚C, 5% 
CO2. Transfection was performed using 25 pmol of Na+ CP 
type Vα siRNA (h) obtained from Santa Cruz Biotechnology 
(cat no. sc-42640). Solution A was prepared following the 
manufacturer's protocol by diluting 1 µl Stemfect RNA trans-
fection reagent (Stemgent, cat no. 00-0069) into 24 µl buffer. 
Solution B was made by diluting 2.5 µl of siRNA transfection 
reagent into 22.5 µl of buffer. Solutions A and B were then 
mixed, incubated for 15 min, and added dropwise to the cells. 
After 48-72 h cells were harvested and RNA extracted for 
determination of SCN5A expression by SYBR-Green real-time 
quantitative PCR as described below.
RNA extraction. RNA was extracted from transfected pII cells 
and purified using the RNeasy kit (Qiagen, uSA) following the 
manufacturer's protocol. The concentration and yield of RNA was 
determined spectroscopically using the Nano-drop (Pharmacia) 
and integrity checked by agarose gel electrophoresis.
Quantitative real-time PCR. RNA was converted to cdNA using 
a High-Capacity cDNA Reverse Transcription kit from Applied 
Biosystems. Quantitative PCR was performed in the ABI 7500 
FAST thermocycler in a reaction volume of 20 µl using the 
SyBER green master mix from Invitrogen). Primers for SCN5A 
gene (forward primer 5'-CACGCGTTCACTTTCCTTC-3', 
reverse primer 5'-CATCAGCCAGCTTCTTCACA-3'; 208-bp 
product) and β-actin were synthesized in the HSC Research 
Core Facility, Kuwait university.
Statistical analysis. Means of various groups were compared 
using the Sudent's t-test. Differences were considered signifi-
cant at p≤0.05.
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Results
VGSC current in pII and MCF-7 cells. Whole-cell patch 
clamp recording revealed that VGSC currents were absent in 
MCF-7 cells (n=8 recordings), consistent with previous reports 
(Fig. 1A) (22). Interestingly, however, ER silencing in pII cells 
resulted in the upregulation of a fast inward Na+ current in 2 of 
5 cells recorded (Fig. 1B-d).
Effect of phenytoin and TTX on pII cell proliferation and 
motility. The effect of various doses (100 nM-100 µM) of PHT 
and TTX on pII cell proliferation was assessed using the MTT 
Figure 1. VGSC currents in MCF-7 and pII cells. (A) Representative trace showing that there was no obvious inward current in MCF-7 cells. (B) pII cell 
exhibiting fast inward VGSC current. (C) Inward and (D) outward current-voltage relationship of pII cells. Cells were held at -120 mV for 250 ms before 
depolarization to voltages ranging from -80 to +30 mV in 5 mV increments for 50 ms.
Figure 2. Effect of PHT and TTX on proliferation and motility of pII cells. Cells grown in microtitre plates were either left untreated (control, open bars) or 
exposed to PHT/TTX at the concentrations indicated. Growth was assessed by MTT assay after 4 days of incubation (A and B). Motility was determined by 
the wound healing assay after 24 h of incubation (C and D). Histobars represent the mean ± SEM of 4-14 independent determinations, *Significant difference 
from control with p≤0.05.
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assay. As shown in Fig. 2A, phenytoin had no effect, while 
TTX exhibited a small inhibitory effect (25-30%) when used at 
the higher concentrations (50-100 µM; Fig. 2B). On the other 
hand, TTX had no effect on cell motility whereas phenytoin 
had a small (8-10%) inhibitory effect at 50-100 µM (Fig. 2C 
and d).
Effect of PHT and TTX on random invasion of pII cells 
towards serum components. The agarose invasion assay 
was used to determine the effect of VGSC inhibitors on pII 
invasion towards serum components. As shown in Fig. 3A 
and C, both drugs exhibited dose-dependent inhibition; 
PHT exerted its effect at 50 and 100 µM with 40 and 50% 
inhibition respectively. TTX exhibited its effect from a lower 
concentration (1 µM) with 25% inhibition. Matrigel invasion 
assay was used to confirm the anti-invasive property of PHT. 
Fig. 3B shows a significant inhibitory effect of PHT at all 
doses used (1-100 µM) with 50% inhibition.
Distribution and expression profile of VGSCs in endocrine 
sensitive and resistant breast cancer cell lines. Immuno-
fluorescence indicated a similar diffuse cytoplasmic as well as 
perinuclear distribution of Nav1.5 in both MCF-7 and pII cells 
(Fig. 4A and B). Measurement of total protein by western 
blotting showed enhanced expression upon EGF stimulation 
(at 50 ng/ml) in pII cells; the cellular distribution of Nav1.5 
remained unchanged (Fig. 4C-E).
Effect of PHT and TTX on invasion of pII cells towards 
EGF. Fig. 5A and B shows a significant increase in the inva-
sive capacity of pII cells towards the well containing EGF 
compared to vehicle (PBS, hatched bars); this was associ-
ated with elevated ERK1/2 phosphorylation and total MMP 
activity (Fig. 5C and D, second line; and E, open circles). 
Both drugs (PHT and TTX) showed similar dose-dependent 
inhibition of the EGF-induced invasion. As shown in Fig. 5B 
and C (line 6), the anti-invasive property of VGSCs was in 
part through reducing EGF-induced ERK1/2 (but not Akt) 
phosphorylation as well as reduction of EGF-induced MMP 
activity (Fig. 5E). In addition, by using the human protease 
profiler kit, we observed that EGF stimulation significantly 
enhanced the levels of cathepsin E, kallikrein-10 and MMP-7 
(Fig. 5F) relative to controls. This effect was significantly 
inhibited by pre-treatment with phenytoin.
Nav1.5 knockdown by siRNA transfection. Fig. 6A shows a 
significant decrease in expression of SCN5A mRNA (80%) at 
48 h post-transfection with targeting siRNA. Knockdown of 
Nav1.5 protein was confirmed by immunofluorescence with 
anti-VGSC antisera. Whereas there was clear cytoplasmic as 
well as perinuclear staining in cells transfected with a scram-
bled sequence the specific siRNA transfected cells showed 
almost no signal (Fig. 6B and C). Cytoskeletal staining with 
phallotoxin was the same in both.
Effect of SCN5A knockdown on pII cell motility and inva-
sion. As shown in Fig. 7A SCN5A mRNA knockdown did not 
affect pII cell motility compared to control, but significantly 
inhibited invasion (50%) towards serum components and EGF 
(Fig. 7B and C).
Discussion
Although VGSCs are mainly expressed in the plasma 
membrane of neuronal cells (28), these channel proteins 
could have roles aside from regulating membrane potential. 
We showed that Nav1.5 is expressed in the cytoplasmic and 
perinuclear region, as well as in the lamellipodia, of highly 
invasive breast cancer cells, suggesting a role in cell migra-
tion and invasion (3,5-7,29). We have previously documented 
that the expression of SCN5A gene (encoding Nav1.5 protein) 
was significantly increased (by 4-fold) in the highly invasive 
ER silenced pII cells compared to the ER+ MCF-7 cells which 
have little invasive capacity (27). In view of these findings, we 
Figure 3. Effect of PHT and TTX on invasion of pII cells towards serum 
components. Cells were either left untreated (control, open bars) or exposed to 
various doses of PHT/TTX. The total number of pII cells penetrating into the 
agarose layer were manually counted as described in Materials and methods 
[control set as 100%; (A and C)]. (B) The effect of phenytoin on penetration of 
cells through a basement membrane extract (BME) using the Matrigel assay 
towards serum components. The y-axis shows arbitrary fluorescence units 
indicating uptake of Calcein into penetrating cells as described in Materials 
and methods. Histobars represent the mean ± SEM of 3-18 independent deter-
minations, *Significant difference from control with p≤0.05.
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investigated the expression and involvement of VGSCs in 
pII cells using whole-cell patch clamp recording, pharma-
cological inhibitors (PHT and TTX) and siRNA-mediated 
knockdown of Nav1.5 protein. Our observations show that 
VGSC currents were only detectable in pII cells, and not in 
MCF-7 cells, suggesting a role in modulating various func-
tions such as cell invasion. upregulation of the SCN5A gene 
in pII cells compared to MCF-7 might explain the absence of 
the VGSC current in latter cells. In addition, cells that have 
undergone EMT (due to ER loss) acquire enhanced invasive 
capacity and upregulate the level/activity of various growth 
factor receptors, signalling and adhesion molecules, as well 
as ion channels. VGSCs can promote cell invasion, in part 
through modulation of EGF-induced ERK1/2 phosphoryla-
Figure 4. Distribution of VGSCs in MCF-7 and pII cells. Cells were seeded into 8-chambered slides and allowed to grow for 48 h at 37˚C/5% CO2. Cells were 
then fixed and stained with Nav1.5 antibody (red), phallotoxin (green) and dAPI (blue). (A) MCF-7. (B and E) pII untreated. (F) pII stimulated with EGF 
10 ng/ml for 30 min. (C) pII cells serum starved for 2 h and then either left untreated (control) or exposed to 10 or 50 ng/ml EGF and subsequently harvested 
at 10 min, 6 h and 24 h. Protein lysates were electrophoresed in 10% SdS-polyacrylamide gel, blotted onto nitrocellulose membrane and probed with antisera 
against Nav1.5 and β-actin. (D) Densitometric analysis of the bands in the blot in (C) expressed as a ratio of Nav1.5/actin for normalisation.
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Figure 5. Effect of PHT and TTX on EGF-induced invasion, protease levels, and MMP activity. (A and B) pII cells were either left untreated (control, open 
bars), treated with EGF (50 ng/ml, hatched bars), or pre-treated with various doses of PHT/TTX plus EGF (solid bars). Total number of cells penetrating into 
the agarose layer were manually counted as described in Materials and methods. (C and D) pII cells were serum starved overnight and either left untreated or 
stimulated with EGF in the presence or absence of PHT/TTX. Protein lysates were electrophoresed on SDS-PAGE and proteins transferred onto nitrocellulose 
membrane and probed with antisera against P-ERK1/2, P-Akt, or actin. (E) pII cells were seeded into 6-well plates and grown until 90% confluent, then serum 
starved overnight. Cells were then treated with EGF (10 and 100 ng/ml) with or without PHT pre-treatment (50 µM, for 1 h). MMP activity was determined 
using a fluorogenic substrate (as described in Materials and methods). (F) Protease levels were determined in pII cells; untreated (solid bars), treated with 
EGF (100 ng/ml, open bars), or treated with phenytoin (50 µM) followed by EGF treatment (100 ng/ml, hatched bars). Histobars represent the mean ± SEM of 
3-14 independent determinations. *Significant difference (with p≤0.05) from control; #EGF treatment.
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tion, protease levels, and MMP activity. We found the same 
pattern of Nav1.5 expression in MCF-7 and pII cells; this local-
ization was not changed by EGF stimulation.
Changes in Na+ fluxes in metastatic cancer cells have 
been shown to regulate intracellular pro-invasive signaling 
cascades, e.g., persistent MAP kinase signaling leading 
to downstream phosphorylation of ERK and other targets 
(30,31). Persistent Na+ currents may contribute to invasion via 
several mechanisms, including: a) allosteric regulation of the 
Na+/H+ exchanger, NHE1, giving rise to extracellular acidifi-
cation (23), b) reverse mode of the Na+/Ca2+ exchanger, NCX, 
potentiating intracellular Ca2+ signaling (32), c) promotion of 
invadopodia formation via src kinase activity and cortactin 
phosphorylation (33), and d) regulation of β1-mediated adhe-
sion-dependent migration and invasion (21). These various 
mechanisms have been reviewed extensively (34,35).
It has been suggested that Fyn kinase activates the fyn-
focal adhesion kinase (FAK)-ERK1/2 pathway, leading to 
neurite outgrowth (36). In MdA-MB-231 breast cancer cells, 
fyn kinase was shown to co-localize with the β1 subunit of 
VGSC, and pharmacological, as well as siRNA-mediated fyn 
inhibition, resulted in inhibition of the β1-mediated process 
outgrowth (which is proposed to be mediated through ERK1/2 
phosphorylation) (21). In Mat-LyLu rat prostate cancer cells, 
EGF treatment (for 24 h) significantly increased VGSC current 
density and cell migration. Importantly, EGF treatment in the 
presence of TTX (a highly selective VGSC blocker) abolished 
65% of the potentiating effect of EGF suggesting that a signifi-
cant portion of the EGF-induced enhancement of migration 
occurred via VGSC activity (37). In our study, we showed 
that EGF treatment significantly enhanced VGSC protein 
expression (Fig. 4) and siRNA-mediated knockdown of VGSC 
inhibited EGF-induced invasion in pII cells (Fig. 7C), which 
is consistent with the data obtained from the prostate cancer 
cells. We also observed a significant inhibition of ERK1/2 
phosphorylation by phenytoin and TTX treatment (Fig. 5) 
consistent with an involvement in VGSC-mediated invasion 
of pII cells.
Phenytoin is an anti-epileptic and class 1b anti-arrhythmic 
agent which inhibits the activity of VGSCs (38). Its binding 
affinity to VGSCs increases when the channels are in the inac-
tivated state (39). Subtypes of VGSCs such as Nav1.5 do not 
reach a complete inactivation state and carry steady-state Na+ 
currents at depolarized potential (40,41). Cancer cells possess 
a more depolarized membrane potential compared to normal 
epithelial or excitable cells, suggesting that some permanent 
Figure 6. VGSC knockdown by siRNA transfection. (A) pII cells were seeded into 12-well plates, allowed to attach overnight and then either transfected with 
a scrambled sequence (open bar) or SCN5A siRNA (solid bar). RNA was extracted from the cells, converted to cDNA and PCR amplified. Ct values were 
converted to ratios as described in Materials and methods. Histobars represent mean ± SEM of 3 independent determinations. *Significant difference from 
control with p=0.026. (B and C) Cells were seeded into a µ-dish35mm, high and incubated at 37˚C/5% CO2 for 24 h, then transfected with scrambled sequence (B) 
or SCN5A siRNA (C). After 48 h, cells were fixed and stained with Nav1.5 antibody (red), phallotoxin (green) or dAPI (blue).
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Na+ current may be involved in invasion and migratory activity 
(3,42). At concentrations (50 µM) that are used in treatment of 
epilepsy, phenytoin significantly inhibits both persistent and 
transient Na+ currents in the de novo resistant breast cancer 
cells MDA-MB-231, resulting in reduction of their invasive 
potential (3,43). Furthermore, phenytoin significantly inhibits 
growth, invasion and metastasis of orthotopic MDA-MB-231 
breast tumors in vivo (44). However, phenytoin had no effect 
on MCF-7 cell migration or invasion (they do not express Na+ 
currents), nor on cell proliferation of either MDA-MB-231 or 
MCF-7 in vitro (3). TTX, also considered a highly specific 
VGSC blocker, is reported to suppress metastatic behaviour 
in human breast, prostate and lung cancer cells in vitro. 
Cell proliferation was also not affected by TTX treatment, 
suggesting involvement specifically in cell invasion (4,8,45). 
We observed similar effects of PTH/TTX in pII cells as potent 
anti-invasive agents (Fig. 3) without significantly modulating 
either cell proliferation or motility. A marginal decrease was 
seen in cell proliferation at higher doses of TTX (50-100 µM; 
Fig. 2B), and a marginal decrease in cell motility with higher 
doses of phenytoin treatment (50-100 µM; Fig. 1C). It should 
be noted that the anti-invasive property of PHT or TTX was 
not due to inhibiting cell proliferation since 24-48-h treatment 
(the time-point used for the invasion assays) did not affect cell 
proliferation with either drug (data not shown). Differences in 
effect on motility and proliferation might be due to the lack 
of specificity of these agents particularly at higher doses. 
Therefore, the siRNA-approach was used to confirm these 
findings in a more specific way. siRNA mediated knockdown 
of VGSCα isoforms has been reported to supress breast cancer 
cell invasion (4,24,45), which is in aggreement with our data in 
pII cells (Fig. 6B and C).
In order to metastasize, cancer cells have to degrade the 
extracellular matrix (ECM) components, and VGSCs have 
been suggested to play a role in this process through Na+/H+ 
exchanger type I (NHE-1) activation. Fraser et al (22) showed 
that VGSCs (specifically Nav1.5) increase Na+ influx, which in 
turn activates the NHE-1 present in caveolae. NHE-1 plays a 
role in Na+ influx regulation, leading to extracellular acidifica-
tion of the tumor microenvironment, resulting in activation of 
pH-dependent extracellular matrix degradation by cysteine 
cathepsins B and S, and subsequent enhancement in cell 
invasion (23). Matrix metalloproteinases (MMPs) are among 
the proteins involved in invasion by virtue of their ability 
to degrade various ECM components including collagens, 
laminin, fibronectin, vitronectin, enactin, tenascin, elastin and 
proteoglycans (46). They are also thought to play a crucial 
role in tumor invasion, metastasis, migration and angiogen-
esis (47,48). Pharmacological blockade of Nav1.5 channels in 
MDA-MB-231 cells result in a significant decrease in MMP-9 
mRNA expression and cell invasion (49), which is also in 
agreement with our finding of increased MMP activity in the 
presence of EGF (Fig. 4E). We showed that the most significant 
inhibitory effect of phenytoin was observed on EGF-induced 
cathepsin E levels (Fig. 4F). Cathepsin E has been suggested 
as a possible marker for pancreatic tumors (50,51), and inter-
estingly, a recent study demonstrated a positive correlation 
between enhanced serum levels of cathepsin E and poor clin-
ical prognosis in breast cancer patients. Mice overexpressing 
cathepsin E demonstrated enhanced tumor growth and metas-
tasis through induction of the EMT process (52).
From a therapeutic viewpoint, VGSC blockade has been 
reported to relieve severe cancer pain in patients receiving 
chemotherapy (53-55). In fact, the newly FDA approved drug, 
Riluzole, blocks VGSC activity and inhibits metabotropic 
glutamine receptor, and was reported to prevent side effects 
related to cancer chemotherapy (56). In addition, Riluzole 
reduced the metabolic activity of tumors in patients with 
resectable stage III and IV melanoma (57). Furthermore, the 
use of VGSC blockers during radical prostatectomy mini-
mized cancer recurrence and metastasis (58,59). Recently, it 
was suggested that further investigation of the FDA-approved 
VGSC blockers which are already in the market (for other 
diseases such as epilepsy and arrhythmia, and for inducing local 
anaesthesia) should be tested for human metastatic diseases. In 
conclusion, our data suggest a promising anti-metastatic role 
for VGSC blockers in acquired forms of endocrine resistance 
in breast cancer.
Figure 7. Effect of SCN5A siRNA knockdown on pII cell motility and invasion. 
Cells were either transfected with scrambled sequence (control, open bars) 
or with SCN5A siRNA (solid bars). Motility (A), and invasion towards serum 
components (B) or EGF (C) was determined as described in Materials and 
methods. Histobars represent the mean ± SEM of 3-6 independent determina-
tions. *Significant difference from control, with p≤0.05.
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